This move is archived. Current quotes and coverage live on the stock page.
Get MIR alerts:
MedMira Inc is facing significant challenges in today's trading session.
MedMira Inc (MIR.V) has seen its stock price drop by 7.14% today, closing at CA$0.07. This decline is concerning for investors who may have hoped for more stability from this small-cap biotech firm.
Advertisement
MedMira Inc
MIR.V
MIR.V
MedMira Inc
WealthAwesomeMarket cap
$49.12M
52W high
$0.11
52W low
$0.05
1W change
+16.67%
Beta
0.76
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MIR's historical volatility
30-Day Vol
112.8%
Annualized
90-Day Vol
105.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.08
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.07 | C$0.05 – C$0.11 |
| 60 trading days | C$0.08 | C$0.05 – C$0.14 |
| 90 trading days | C$0.08 | C$0.04 – C$0.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain cautious as MedMira's recent performance raises concerns about its market position and future prospects.
MedMira Inc's stock plummets by 7.14%
With a market cap of CA$49.12 million, the company's stock performance today raises questions about investor sentiment and market viability.
Bull case
Despite today's downturn, MedMira has made progress in securing regulatory approvals for its products. These approvals could lead to future growth opportunities.
Bear case
The sharp drop in stock price today highlights potential weaknesses in MedMira's operational performance and market confidence.
Advertisement
Understanding the Decline
MedMira's stock price has fallen significantly in today's trading session, reflecting investor concerns over the company's recent performance. With no major news announcements to counterbalance the downward trend, the market seems to be reacting to broader uncertainties surrounding small-cap biotech stocks.
Market Sentiment and Future Outlook
The 7.14% drop in MedMira's stock raises questions about investor confidence. While the company has made notable advancements in product approvals, the lack of immediate positive developments may have contributed to today's sell-off. Investors should keep an eye on upcoming announcements, as they could influence future market performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
